In a “ground breaking ceremony” led by MP for Salisbury John Glen, Porton Biopharma Ltd (PBL) has initiated the construction of a new multi-million pound facility. The investment will see the creation of a pharmaceutical process facility that contains a new large state-of-the-art fermenter, process train and associated utilities.
PBL has enjoyed considerable success during its first year of operation by meeting all of our milestones and by investing in both staff and facilities.
George Freeman MP, Minister for Life Sciences, today opened our new multi-million pound pharmaceutical manufacturing facility. He was accompanied by John Glen, MP for Salisbury, along with Richard Walters, Alistair Cunningham and Baroness Jane Scott from Wiltshire Council
Porton Biopharma limited (PBL) is working with Ohara Pharmaceutical Co., Ltd. who has today submitted a New Drug Application for Erwinase® in Japan. The submission was specifically timed because the 17th December is considered to be “a lucky day” in the Japanese Rokuyo calendar and is known as Taian, 大安 . This is an auspicious good luck day for all concerned and is particularly good for wedding ceremonies and starting new business ventures, hence why it was chosen.
Developing links with a range of academic institutions, industry professionals and the local community is a key component of PBL’s engagement and marketing strategy. This will enable us to keep up to date with latest research and innovative thinking, provide cross-linkages with academic and industry partners, and also develop potential career paths to enhance our workforce planning.
We are pleased to announce that Dave Gervais, a Senior Scientist and Analytical Innovation Lead at PBL has been awarded the degree of Doctor of Philosophy from Oxford Brookes University.
Martin Hindle, Chairman of the newly formed company Porton Biopharma Limited (PBL), today opened an extension to its Pharmaceutical stores (Pharm-Stores).
We are pleased to announce that Pat Mills, Commercial Director at the Department of Health has taken up a role as a Shareholder Director of PBL,